Eli Lilly and Company (NYSE:LLY – Get Free Report) is expected to issue its quarterly earnings data before the market opens on Thursday, February 6th. Analysts expect the company to announce earnings ...

Eli Lilly and Company (NYSE: LLY) has recently received a number of price target changes and ratings updates: 2/3/2025 – Eli Lilly and Company had its price target raised by analysts at Truist ...

Eli Lilly and Company discovers ... Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin ...

It turns out that the anti-obesity space isn't growing as fast as Eli Lilly or analysts anticipated, resulting in ...

AbbVie, Eli Lilly and Company, Vertex Pharmaceuticals, Thermo Fisher Scientific, and Johnson & Johnson are the five ...

and fast-acting insulin Humalog. And that's before we get into the company's pipeline, which features plenty of investigational drugs beyond Eli Lilly's core area of diabetes and obesity.

Eli Lilly’s big-selling insulin, Humalog, faces cut-price competition after the US regulator approved a biosimilar from Sanofi. Sanofi’s Admelog (insulin lispro) is approved in type 1 and type ...

Indianapolis-based drugmaker Eli Lilly and Company has announced price reductions ... effective as of Q4 2023. Both Humalog and Insulin Lispro Injection are fast-acting insulins, they are used ...

1,2 The Egyptian Drug Authority approved the insulin glargine injection manufactured by EVA Pharma through a collaboration with Eli Lilly and Company (NYSE: LLY). Launched in 2022, the ...